CDH1 and breast carcinoma: Aberrant methylation has paramount consequences on tumor biology (i) for the activation of alternative transcription-start sites and the release of pluripotency loci from DNA-methylation repression, or (ii) for the blockade of transcription at methylated regions corresponding to oncosuppressors, for epigenetic silencing programs of miRNAs and of relevant adhesion molecules like E-cadherin.1, 5 Methylation of CDH1 gene with transcriptional silencing of E-cadherin, an epithelial-specific biomarker, occurs in primary breast carcinoma but not in bone metastasis.6, 7